RADX vs PRTC vs ROIV vs RNW

For growth investors, Radiopharm Theranostics Limited (RADX) is the stronger pick with 1114% revenue growth year-over-year, versus -11.

2% for Roivant Sciences Ltd. (ROIV). ReNew Energy Global Plc (RNW) offers the better valuation at 48. 6x trailing P/E (0. 4x forward), making it the more compelling value choice. Analysts rate PureTech Health plc (PRTC) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Roivant Sciences Ltd.

(ROIV) delivered a total return of +187. 6%, compared to -77. 4% for Radiopharm Theranostics Limited (RADX). Over 10 years, the gap is even starker: ROIV returned +174. 6% versus RADX's -77. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), PureTech Health plc (PRTC) is the lower-risk stock at 0.

51β versus Roivant Sciences Ltd. 's 0. 96β — meaning ROIV is approximately 87% more volatile than PRTC relative to the S&P 500. On balance sheet safety, Roivant Sciences Ltd. (ROIV) carries a lower debt/equity ratio of 2% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Radiopharm Theranostics Limited (RADX) is pulling ahead at 1114% versus -11.

2% for Roivant Sciences Ltd. (ROIV). On earnings-per-share growth, the picture is similar: Radiopharm Theranostics Limited grew EPS 85. 3% year-over-year, compared to -24. 0% for PureTech Health plc. Over a 3-year CAGR, RADX leads at 643. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ReNew Energy Global Plc (RNW) is the more profitable company, earning 3.

9% net margin versus -23. 6% for PureTech Health plc — meaning it keeps 3. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus -34. 5% for ROIV. At the gross margin level — before operating expenses — PRTC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRTC: 232.

6% to $57. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, PureTech Health plc (PRTC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

51)). Both have compounded well over 10 years (PRTC: -55. 5%, RADX: -77. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RADX (Healthcare) and PRTC (Healthcare) and ROIV (Healthcare) and RNW (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RADX is a small-cap high-growth stock; PRTC is a small-cap quality compounder stock; ROIV is a mid-cap quality compounder stock; RNW is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.